GASTROClear Stomach Cancer Test: For Healthcare Professionals

GASTROClear stomach cancer test is a minimally invasive blood test designed to aid in the early detection and risk assessment of gastric (stomach) cancer. The test utilises a proprietary PCR-based technology developed by MiRXES. It quantifies the expression levels of a specific panel of 12 microRNAs (miRNAs) in a patient’s blood. These miRNAs have been identified through clinical research as biomarkers that are strongly associated with the presence of gastric cancer. The assay can detect stomach cancer across all stages, from stage 0 (high-grade dysplasia) through Stage IV.

Back To: DNA Testing For Stomach Cancer Big Story

Technical Overview And Performance

GASTROClear measures microRNAs – small non-coding RNA molecules that regulate gene expression and play critical roles in cellular processes. Aberrant levels of these miRNAs are linked with cancerous changes. This makes them valuable biomarkers for early disease detection. The test’s platform employs reverse transcription quantitative PCR (RT-qPCR) technology to precisely measure the concentration of these 12 miRNAs. It combines their expression patterns into an algorithm-generated risk score that indicates the patient’s likelihood of gastric cancer being present at the time of testing.

Clinical validation involved over 5,000 participants in prospective studies conducted in Singapore and Korea. Participants included symptomatic high-risk patients referred for gastroscopy. During these trials, GASTROClear achieved an overall sensitivity of approximately 81–87% and specificity between 68–90%, depending on the cohort and study design. The assay demonstrated a sensitivity of above 80% across all gastric cancer stages, ages, genders, and ethnicities. This outperforms conventional blood-based biomarkers like Helicobacter pylori serology, pepsinogen indices, and tumor markers (CEA and CA 19-9) by a margin of at least 20% in cancer detection accuracy.

The Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) for GASTROClear was reported around 0.85. This is indicative of excellent diagnostic performance. Importantly, the test also showed minimal cross-reactivity with other common cancers including those of the gastrointestinal tract. This supports its specificity for gastric cancer detection.

GASTROClear Stomach Cancer Test: Clinical Indications And Use

GASTROClear is intended primarily as a screening or triaging tool for:

• Adults aged 40 and above, especially those with additional risk factors such as family history of gastric cancer or symptoms suggestive of gastric pathology.
• Patients referred for gastroscopy where a non-invasive test may support prioritisation of diagnostic procedures.
• Individuals concerned about gastric cancer risk seeking a less invasive option compared to initial gastroscopy.

GASTROClear is not a diagnostic replacement for gastroscopy and biopsy. It is instead a complementary test aimed at providing a risk stratification score (low, intermediate, or high) to aid in clinical decision-making. High-risk scores may warrant further endoscopic evaluation; low-risk scores on the other hand, may support clinical monitoring or reassurance depending on the clinical context.

Contraindications And Limitations

There are no absolute contraindications documented for GASTROClear given its non-invasive blood-based nature. However, there are certain factors which may affect test performance or interpretation. For instance, the presence of other malignancies or systemic diseases could potentially affect circulating miRNA levels and confound results. Likewise, patients currently undergoing cancer treatment or have recent surgical interventions might not be ideal candidates until they have stabilised.

GASTROClear Stomach Cancer Test Reported Issues And Adverse Effects

Since GASTROClear involves only a single tube of blood being drawn, it carries a low risk profile typical of routine venipuncture procedures. There are no specific adverse effects attributed to the test itself beyond standard blood draw discomfort or bruising.

Some reports in medical community forums and anecdotal accounts have noted variability in results potentially related to technical factors such as sample handling or biological variability in miRNA expression. However, these are not formally validated or published in peer-reviewed studies to date. The test’s reliance on complex molecular signatures necessitates rigorous quality control and interpretation within clinical context to minimise false positives or negatives (Reference: GASTROClear Instructions For Use).

Additional Information Of Interest

GASTROClear represents one of the first clinically validated miRNA-based assays targeting gastric cancer in an Asian population, a group with a high gastric cancer burden. Its development addresses the unmet need for sensitive, specific, and minimally invasive tools that encourage early detection and increase screening uptake compared to traditional endoscopy, which is more invasive, expensive, and sometimes not tolerated well by patients.

The test requires only 5 mL of serum collected in standard blood tubes, without fasting or special preparation, allowing ease of integration into routine clinical practice. Results are typically returned within a week, facilitating timely decision-making.

GASTROClear offers medical professionals a robust, evidence-backed option to augment gastric cancer screening and early detection. Its validated accuracy, ease of use, and low patient burden make it an important addition to the diagnostic toolkit for managing patients at risk of stomach cancer.

Contact Us

For healthcare professionals – for business opportunities:

• MCNAsia – Preferred Doctor, SEO, Website Development, Influencer Marketing, and RED (Xiaohongshu) Marketing

For non-healthcare professionals seeking an appointment for GASTROClear screening, contact us for assistance via the button below

Back To: DNA Testing For Stomach Cancer Big Story

.